News

05.14.2026  |  Press Release

Tessera Therapeutics Showcases New Preclinical Data Advancing In Vivo Program in Sickle Cell Disease and CAR-T Applications at the American Society of Gene and Cell Therapy 29th Annual Meeting

By Tessera Therapeutics

04.27.2026  |  Press Release

Tessera Therapeutics to Present New Preclinical Data Supporting In Vivo Program in Sickle Cell Disease and Advancements in In Vivo CAR-T Applications at the American Society of Gene and Cell Therapy 29th Annual Meeting

By Tessera Therapeutics

03.23.2026  |  Press Release

Tessera Therapeutics Receives Grant to Advance In Vivo Gene Writing Approaches Towards a Potential Human Immunodeficiency Virus (HIV) Cure

By Tessera Therapeutics

02.23.2026  |  Press Release

Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for the Treatment of Adults with AATD

By Tessera Therapeutics

01.12.2026  |  Press Release

Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD

By Tessera Therapeutics

12.09.2025  |  Press Release

Tessera Therapeutics Announces Chief Financial Officer (CFO) Transition and Appointment of Kathy Bergsteinsson as CFO

By Tessera Therapeutics

12.08.2025  |  Press Release

Tessera Therapeutics Showcases New Preclinical Data Demonstrating Progress of In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting

By Tessera Therapeutics

12.01.2025  |  Press Release

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

By Tessera Therapeutics

11.03.2025  |  Press Release

Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting

By Tessera Therapeutics